DOCSLIB.ORG

Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk Iii PT Kimia Farma (Persero) Tbk Annual Report 2014 Kinerja KAEF I KAEF Performance

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk Iii PT Kimia Farma (Persero) Tbk Annual Report 2014 Kinerja KAEF I KAEF Performance PT KIMIA FARMA (PERSERO) Tbk I C A R E I C A R E PT KIMIA FARMA (PERSERO) Tbk Jl. Veteran no. 9, Jakarta 10110 Telp. (021) 384 7709 Fax. (021) 381 4441 Email: [email protected] Website: www.kimiafarma.co.id Kinerja KAEF KAEF Performance 148,17% Kapitalisasi Pasar Meningkat Kapitalisasi pasar saham meningkat 148,17% dari Rp3,28 triliun Market Capitalization Increased pada tahun 2013 menjadi Rp8,14 triliun pada tahun 2014. Stock market capitalization increased by 148.17%, from IDR3.28 trillion in 2013 to IDR8,14 trillion in 2014. 20,08% Aset Meningkat Aset meningkat 20,08% dari Rp2,47 triliun pada tahun 2013 menjadi Assets Increased Rp2,97 triliun pada tahun 2014. Asset increased by 20.08%, from IDR2.47 trillion in 2013 to IDR2.97 trillion in 2014. 16,58% Laba Usaha Meningkat Laba usaha meningkat 16,58% dari Rp293,77 miliar menjadi Rp342,48 Operational Profit Increased miliar. Operational profit increased by 16,58%, from IDR293,77 billion in 2013 to IDR342,48 billion in 2014. 9,36% Laba Bersih Meningkat Laba bersih meningkat 9,36% dari Rp214,55 miliar pada tahun 2013 Net Profit Increased menjadi Rp234,63 miliar pada tahun 2014 dan melebihi anggaran 0,51%. Net profit increased by 9.36%, from IDR214.55 billion in 2013 to IDR234.63 billion in 2014, which exceeded the Budget by 0.51%. 45,47% Kas Meningkat Kas meningkat 45,47% dari Rp394,15 miliar pada tahun 2013 menjadi Cash Increased Rp573,36 miliar pada tahun 2014. Cash increased by 45.47%, from IDR394.15 billion in 2013 to IDR573.36 billion in 2014. 3,98% Penjualan Meningkat Penjualan meningkat 3,98% dari Rp4,35 triliun pada tahun 2013 menjadi Sales Increased Rp4,52 triliun pada tahun 2014, dan tercapai 87,78% dari anggaran. Sales increased by 3.98%, from IDR4.35 trillion in 2013 to IDR4.52 trillion in 2014, which achieved 87.7% of the Budget. Produk Perseroan baik bahan baku, sediaan farmasi dan produk obat jadi diekspor ke beberapa negara antara lain: Eropa, Asia, Selandia Baru dan Uni Emirat Arab. The Company’s products which includes raw materials, pharmaceutical preparations and patent medicine are exported to several countries including Europe, Asia, New Zealand and United Arab Emirates. Daftar Isi Table of Contents Kinerja KAEF i KAEF Performance Ikhtisar Keuangan 1 Financial Highlights Perdagangan Saham KAEF 3 KAEF Stocks Trading Aksi Korporasi 4 Corporate Action Profil Perseroan 7 Company Profile Penghargaan 14 Awards Peristiwa Penting 16 Event Highlights Laporan Manajemen 19 Management’s Reports Bidang dan Kegiatan Usaha 33 Business Sectors and Activities Organisasi 51 The Organization Analisa dan Tinjauan Manajemen atas Kinerja Perusahaan 67 Management’s Discussion and Analysis on the Company’s Performance Tata Kelola Perusahaan 111 Good Corporate Governance Tanggung Jawab Sosial Perseroan 165 Corporate Social Responsibility Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk iii PT Kimia Farma (Persero) Tbk Annual Report 2014 Kinerja KAEF i KAEF Performance Ikhtisar Keuangan 1 Financial Highlights Ikhtisar Keuangan Perdagangan Saham KAEF 3 KAEF Stocks Trading Financial Highlights Aksi Korporasi 4 Corporate Action Profil Perseroan 7 Company Profile Penghargaan 14 Awards Peristiwa Penting 16 Event Highlights Laporan Manajemen 19 Management’s Reports Bidang dan Kegiatan Usaha 33 Business Sectors and Activities Organisasi 51 The Organization Analisa dan Tinjauan Manajemen atas Kinerja Perusahaan 67 Management’s Discussion and Analysis on the Company’s Performance Tata Kelola Perusahaan 111 Good Corporate Governance Tanggung Jawab Sosial Perseroan 165 Corporate Social Responsibility Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk PT Kimia Farma (Persero) Tbk Annual Report 2014 1 Ikhtisar Keuangan Financial Highlights Neraca, Laporan Laba Rugi & Rasio-Rasio Keuangan 2010-2014 Balance Sheet, Loss Profit Statements & Financial Ratios 2010-2014 2014 2013 2012 2011 2010 NERACA (dalam juta rupiah) Balance Sheet (in million rupiah) KAS Cash 573.360 394.150 316.498 199.386 265.446 PIUTANG DAGANG Account Receivable 514.930 546.576 458.728 384.037 357.712 TOTAL ASET LANCAR Total Current Asset 2.040.431 1.810.615 1.505.798 1.263.030 1.139.549 TOTAL ASET TETAP Total Fixed Asset 557.939 498.644 449.140 426.720 413.197 TOTAL ASET Total Assets 2.968.185 2.471.940 2.076.348 1.794.400 1.657.292 UTANG USAHA Account Payable 505.219 477.892 341.133 284.234 300.987 TOTAL LIABILITAS LANCAR Total Current Liability 854.812 746.123 537.184 459.694 469.823 TOTAL LIABILITAS TIDAK LANCAR Total Non-Current Liability 302.229 101.462 97.630 82.043 73.435 TOTAL LIABILITAS Total Liability 1.157.041 847.585 634.814 541.737 543.257 JUMLAH EKUITAS Total Equity 1.789.213 1.608.225 1.426.497 1.252.660 1.114.034 JUMLAH INVESTASI Total Investment 349.270 199.269 81.802 42.334 38.353 MODAL KERJA BERSIH Net Working Capital 1.185.618 1.064.492 968.614 803.336 669.726 LAPORAN LABA RUGI (dalam juta rupiah) Loss Profit Statements (in million rupiah) TOTAL PENJUALAN Total Sales 4.521.024 4.348.074 3.734.241 3.481.166 3.183.829 LABA KOTOR Gross Profit 1.385.482 1.292.152 1.175.167 1.038.016 904.519 TOTAL BEBAN USAHA Total Operating Expense 1.099.831 1.042.619 912.599 816.012 758.321 LABA USAHA Operating Profit 342.480 293.765 262.567 222.003 146.198 LABA (RUGI) SEBELUM PAJAK Profit (Loss) Before Tax 315.611 284.125 278.284 232.007 178.611 LABA (RUGI) BERSIH Net Profit (Loss) 234.625 214.550 205.133 171.765 138.716 LABA (RUGI) BERSIH PER SAHAM (rupiah) Net Profit (Loss) per Share (rupiah) 42.24 38.63 36.93 30.93 24.98 RASIO-RASIO KEUANGAN Financial Ratios IMBAL HASIL Investasi (%) Return on Investment 11,54 11,88 13,73 13,60 11,64 IMBAL HASIL Ekuitas (%) Return on Equity 13,11 13,34 14,38 13,71 12,45 IMBAL HASIL ASET (%) Return on Asset 7,90 8,68 9,88 9,57 8,37 MARGIN LABA KOTOR (%) Gross Profit Margin 30,65 29,72 31,47 29,82 28,41 MARGIN LABA BERSIH (%) Net Profit Margin 5,19 4,93 5,49 4,93 4,36 RASIO Perputaran ASET (%) Asset Turnover Ratio 166,21 191,20 179,66 201,72 197,56 RASIO LANCAR Current Ratio 2,39 2,43 2,80 2,75 2,43 RASIO Cepat Quick Ratio 1,58 2,43 1,82 1,76 1,60 RASIO Utang JANGKA PANJANG (%) Long Term Debt Ratio 26,12 11,97 15,38 15,14 13,52 RASIO Liabilitas TERHADAP JUMLAH ASET (%) Liability to Total Asset Ratio 38,98 34,29 30,57 30,19 32,78 RASIO Liabilitas TERHADAP Ekuitas (%) Liability to Equity Ratio 64,67 52,70 44,50 43,25 48,77 Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk 2 PT Kimia Farma (Persero) Tbk Annual Report 2014 Ikhtisar Keuangan Financial Highlights Perdagangan Saham KAEF KAEF Stocks Trading Perdagangan Saham Periode Januari 2013–Desember 2014 Stocks Trading on January 2013–December 2014 Period Harga Pasar Peredaran Saham di Pasar Reguler Market Price Circulation of Shares in Reguler Market Bulan Tertinggi Terendah Terakhir Volume Nilai Frekuensi Kapitalisasi Pasar Month Highest Lowest Closing Volume Value Frequency Market Capitalisation 2013 (Rp) (Rp) (Rp) Unit (Rp) (x) (Rp) JANUARY 1.050 710 1.030 228.826.500 204.015.095.000 7.751 5.720.620.000.000 FEBRUARY 1.140 970 1.090 164.549.500 173.411.465.000 8.250 6.053.860.000.000 MARCH 1.160 1.030 1.080 175.271.500 191.570.965.000 13.433 5.998.320.000.000 APRIL 1.090 960 990 94.964.500 96.641.465.000 6.022 5.498.460.000.000 MAY 1.040 890 960 116.944.500 113.346.465.000 7.149 5.331.840.000.000 JUNE 980 840 890 49.458.500 44.953.415.000 4.125 4.943.060.000.000 JULY 910 790 790 22.850.500 19.658.215.000 2.558 4.378.660.000.000 AUGUST 810 460 495 76.763.500 41.238.545.000 9.458 2.749.230.000.000 SEPTEMBER 670 420 550 94.478.000 51.744.732.500 5.800 3.054.700.000.000 OCTOBER 720 520 630 56.331.000 34.805.015.000 3.862 3.449.020.000.000 NOVEMBER 640 480 510 46.586.000 26.214.622.500 3.276 2.832.540.000.000 DECEMBER 590 495 590 45.656.500 24.422.450.000 2.730 3.276.860.000.000 Total 1.172.680.500 1.022.022.450.000 74.414 53.287.170.000.000 2014 (Rp) (Rp) (Rp) Unit (Rp) (x) (Rp) JANUARY 745 745 690 133.610 1.441.596.000 11.212 3.832.260.000.000 FEBRUARY 795 795 750 123.927 1.568.463.500 9.404 4.165.500.000.000 MARCH 925 925 900 140.408 1.844.259.000 10.873 4.998.600.000.000 APRIL 945 945 915 72.488 2.352.240.000 7.568 5.081.910.000.000 MAY 1.055 1.055 1.050 119.535 7.969.907.500 10.197 5.831.700.000.000 JUNE 1.090 1.090 990 71.768 2.026.103.000 8.407 5.498.460.000.000 JULY 1.270 1.270 1.230 133.964 3.728.017.000 8.741 6.831.420.000.000 AUGUST 1.370 1.370 1.320 4.444.800 5.815.633.500 7.024 7.331.280.000.000 SEPTEMBER 1.370 1.370 1.150 276.300 317.153.000 4.671 6.387.100.000.000 OCTOBER 1.210 1.210 1.115 7.803.200 8.992.367.500 6.046 6.192.710.000.000 NOVEMBER 1.405 1.405 1.390 2.183.400 2.971.494.500 8.088 7.720.060.000.000 DECEMBER 1.640 1.640 1.465 1.361.700 1.989.251.500 13.889 8.136.610.000.000 Total 16.865.100 41.016.486.000 105.749 72.007.610.000.000 Pergerakan Saham Januari 2013–Desember 2014 Stocks Movement on January 2013–December 2014 Market Cap 2013 2014 Price 1.600 9.000.000.000.000 1.465 1.390 1.400 1.320 8.000.000.000.000 1.230 1.150 1.155 7.000.000.000.000 1.200 1.090 1.080 1.030 1.055 990 6.000.000.000.000 990 1.000 960 900 915 890 790 5.000.000.000.000 750 800 690 630 550 4.000.000.000.000 590 600 510 495 3.000.000.000.000 400 2.000.000.000.000 200 1.000.000.000.000 Jan Feb Mar Apr Mei Jun Jul Agu Sep Okt Nov Des Jan Feb Mar Apr Mei Jun Jul Agu Sep Okt Nov Des ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘13 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 ‘14 Laporan Tahunan 2014 PT Kimia Farma (Persero) Tbk PT Kimia Farma (Persero) Tbk Annual Report 2014 3 Aksi Korporasi Corporate Action Pada tahun 2014, Perseroan memiliki 2 (dua) aksi In 2014, there were 2 (two) corporate actions applied by korporasi yaitu penerbitan Surat Utang Jangka Menengah the Company, namely Medium Term Notes issuance and (Medium Term Notes/MTN) dan penyertaan saham 10% investment in share at PT Asuransi Jiwa InHealth PT Asuransi Jiwa InHealth Indonesia sebesar 10%.
Load more

Recommended publications
  • State-Owned Enterprise Governance and Privatization Program
    Completion Report Project Number: 32517 Loan Number: 1866 November 2008 Indonesia: State-Owned Enterprise Governance and Privatization Program CURRENCY EQUIVALENTS Currency Unit – rupiah (Rp) At Appraisal At Program Completion (28 February 2000) (7 October 2005) Rp1.00 = $0.000137 $0.000097 $1.00 = Rp7,305 Rp10,305 ABBREVIATIONS ADB – Asian Development Bank MOF – Ministry of Finance MSOE – Ministry of State-Owned Enterprises OECD – Organisation for Economic Co-operation and Development PPP – public-private partnership PSO – public service obligation SCI – statement of corporate intent SOE – state-owned enterprise TA – technical assistance NOTES (i) The fiscal year (FY) of the Government ends on 31 December. “FY” before a calendar year denotes the year in which the fiscal year ends. (ii) In this report, “$” refers to US dollars. Vice President C. Lawrence Greenwood, Jr., Operations Group 2 Director General A. Thapan, Southeast Asia Department (SERD) Director J. Ahmed, Governance, Finance, and Trade Division, SERD Team leader K.-P. Kriegsmann, Senior Financial Sector Specialist, SERD CONTENTS Page BASIC DATA i I. PROGRAM DESCRIPTION 1 II. EVALUATION OF DESIGN AND IMPLEMENTATION 2 A. Relevance of Design and Formulation 2 B. Program Outputs 3 C. Program Costs and Disbursements 10 D. Program Schedule 10 E. Implementation Arrangements 10 F. Conditions and Covenants 11 G. Related Technical Assistance 11 H. Consultant Recruitment and Procurement 12 I. Performance of Consultants, Contractors, and Suppliers 12 J. Performance of the Borrower and the Executing Agency 12 K. Performance of the Asian Development Bank 12 III. EVALUATION OF PERFORMANCE 13 A. Relevance 13 B. Effectiveness in Achieving Outcome 13 C. Efficiency in Achieving Outcome and Outputs 14 D.
    [Show full text]
  • Covid: Reused Nose Swab Scam Busted in Indonesia Airport - BBC News 5/6/21, 16:22 Covid: Reused Nose Swab Scam Busted in Indonesia Airport 1 Day Ago
    Covid: Reused nose swab scam busted in Indonesia airport - BBC News 5/6/21, 16:22 Covid: Reused nose swab scam busted in Indonesia airport 1 day ago EPA Covid nasal swab testing has become routine in many countries hit by the global pandemic (file picture) Several employees of a pharmaceutical company have been arrested in Indonesia for allegedly washing and reselling used Covid nasal swab test kits. Up to 9,000 passengers at an airport in Medan may have been tested with the reused swab sticks, say police. State-owned company Kimia Farma is now reportedly facing a potential lawsuit launched on behalf of the travellers. https://www.bbc.com/news/world-asia-56990253 Page 1 of 3 Covid: Reused nose swab scam busted in Indonesia airport - BBC News 5/6/21, 16:22 Covid nasal swab testing has become routine in many countries hit by the global pandemic. Police said they believed the scam had been happening since last December at Kualanamu airport in Medan, North Sumatra. Passengers are required to have a negative test if they want to fly, and the airport offers the option of getting the swabs done on site. Airport authorities had used antigen rapid test kits supplied by Kimia Farma. Following complaints from passengers that they had received false positive test results, police sent an undercover officer to pose as a passenger last week, reported local news outlet Detik. When he was swabbed and received a positive test result, other officers swooped in and raided the test site, where they found a used test kit that had been recycled.
    [Show full text]
  • YAYASAN AKRAB PEKANBARU Jurnal AKRAB JUARA Volume 6 Nomor 2 Edisi Mei 2021 (222-235) 222 MANAJEMEN REPUTASI DAN PEMBENTUKAN CITR
    YAYASAN AKRAB PEKANBARU Jurnal AKRAB JUARA Volume 6 Nomor 2 Edisi Mei 2021 (222-235) MANAJEMEN REPUTASI DAN PEMBENTUKAN CITRA PT KIMIA FARMA TBK DALAM KASUS DAUR ULANG ALAT RAPID TEST COVID-19 -------------------------------------------------------------------------------------------------- Susilowati Fakultas Komunikasi dan Bahasa Universitas Bina Sarana Informatika (Naskah diterima: 1 Maret 2021, disetujui: 30 April 2021) Abstract The demand of a company is to always maintain its reputation, because the company or organization will continue to be monitored by the public for everything that the company does and operates. Building a reputation took a long time to build it, but in seconds everything was destroyed with the Covid-19 rapid test tool recycling case at Kualanamu Airport, so the reputation of PT Kimia Farma Tbk was destroyed, so it needed reputation management and image building in this case. The research objective was to analyze in depth the reputation management and image formation of PT Kimia Farma Tbk in the case of recycling the Covid-19 rapid test tool. The research used a descriptive qualitative approach with news content analysis methods on several online media. The results of the research of PT Kimia Farma Tbk, conducted 4 stages in dealing with reputation, Fact Finding; has conducted real problem research, then Planning and Programming; where the company submits those guilty to legal channels, plans actions to fill vacancies at Kualanamu airport, third, namely Action and Communicating; Refresher management and company internal ensuring all KFD clinics and laboratories throughout Indonesia have fulfilled and implemented KFD SOPs, held a General Meeting Extraordinary Shareholders, dismissed the President Director and the Director of KFD I, internal restructuring, finally, Evaluation; conducting inspections to ensure that KFD clinical and laboratory practices are in accordance with the SOP.
    [Show full text]
  • The Effects of Experience, Complexity, and Computer Self Efficacy Factors Towards the Use of Human Resources Information System Application
    Quest Journals Journal of Research in Business and Management Volume 2 ~ Issue 11 (2014) pp: 26-33 ISSN(Online) : 2347-3002 www.questjournals.org Research Paper The Effects of Experience, Complexity, and Computer Self Efficacy Factors towards The Use of Human Resources Information System Application Teuku Noerman Human Capital Advisor of PT. Kimia Farma (Persero) Tbk., Indonesia Received 13 December, Accepted 31 December, 2014 © The author(s) 2014. Published with open access at www.questjournals.org ABSTRACT:- Information Technology is used to improve either individual or organizational performance. The importance of the use of information technology within the organization is expected to improve the effectiveness and efficiency in working. The aims of this research are examining the effects of Experience, Application Complexity, and Computer Self Efficacy in the implementation of human resources information system application of PT. Kimia Farma (Persero), Tbk., through the media of perceived usefulness, perceived ease of use, behavioral intention, and also actual usage. The research was located on the main company of PT. Kimia Farma (Persero), Tbk, which consists of a Headquarter in Jakarta, and the factories spread in Medan, Jakarta, Bandung, Semarang, and Watudakon (East Java).The technique used to answer the hypothesis of the research isGeneralized Structured Component Analysis (GSCA). Based on the results of the research, it was concluded that the effect of computer experience, application complexity, and computer self efficacy towards the use of human resources information system application of PT. Kimia Farma (Persero), Tbk.,through the media of perceived usefulness, perceived ease of use, behavioral intention. It means that if the application is perceived to be easy and useful, and the user had an intention to use it, the frequency of the use of human resources information system application of PT.
    [Show full text]
  • Situation Update Response to COVID-19 in Indonesia As of 12 October 2020
    Situation Update Response to COVID-19 in Indonesia As of 12 October 2020 As of 12 October, the Indonesian Government has announced 333,449 confirmed cases of COVID-19 in all 34 provinces of Indonesia, with 11,844 confirmed deaths from the virus, and 255,027 people that have recovered from the illness. The government has also reported 152,286 suspected cases. With a population of 260 million people, Indonesia currently has 376 laboratories with a combined testing capacity of 40,000 specimens per day. On the occasion of the commemoration of World Mental Health Day on 10 October, the Indonesian Clinical Psychologists Association announced that its members have treated 14,619 people between March and August 2020, with most common issues addressed linked to learning difficulties, anxiety, stress, mood disorders and depression. Meanwhile, a study conducted by the Indonesian Psychiatrists Association between April and August found that 57.6 percent of the study participants were having symptoms of depression. The psychological impact of COVID-19 is triggered by various factors including the unknown ending of the pandemic, unavailability of treatments and vaccine, social stigma, job losses, and changes in human interaction. The Food and Drug Monitoring Agency (BPOM) of Indonesia has issued the emergency use authorization of two antiviral drugs, namely favipiravir and remdesivir, to treat COVID-19 patients. The BPOM has also granted permits to several pharmaceutical companies to produce the drugs locally. in addition, by the end of 2020, the government expects to secure 670,000 vials of remdesivir from foreign sources. The requisites for the procurement and distribution of vaccines against COVID-19 have been stipulated through Presidential Regulation Number 99 of 2020, issued on 5 October 2020.
    [Show full text]
  • Responsive COVID-19 Vaccines for Recovery Project Under the Asia Pacific Vaccine Access Facility (Guaranteed by the Republic of Indonesia)
    Report and Recommendation of the President to the Board of Directors Project Number: 54425-001 March 2021 Proposed Loan PT Bio Farma (Persero) Responsive COVID-19 Vaccines for Recovery Project under the Asia Pacific Vaccine Access Facility (Guaranteed by the Republic of Indonesia) Distribution of this document is restricted until it has been approved by the Board of Directors. Following such approval, ADB will disclose the document to the public in accordance with ADB’s Access to Information Policy. CURRENCY EQUIVALENTS (as of 5 March 2021) Currency unit – rupiah (Rp) Rp1.00 = $0.0000697 $1.00 = Rp14,349 ABBREVIATIONS ADB – Asian Development Bank AEFI – adverse event following immunization APVAX – Asia Pacific Vaccine Access Facility Bio Farma – PT Bio Farma (Persero) COVID-19 – coronavirus disease Indofarma – PT Indofarma Tbk LIBOR – London interbank offered rate M&E – monitoring and evaluation MOH – Ministry of Health PAM – project administration manual RRC – rapid response component TA – technical assistance UNICEF – United Nations Children’s Fund VAP – Vaccination Allocation Plan VIRAT – Vaccination Introduction Readiness Assessment Tool WHO – World Health Organization NOTE In this report, “$” refers to United States dollars. Vice-President Ahmed M. Saeed, Operations 2 Director General Ramesh Subramaniam, Southeast Asia Department (SERD) Directors Ayako Inagaki, Human and Social Development Division (SEHS), SERD Winfried Wicklein, Country Director, Indonesia Resident Mission (IRM), SERD Said Zaidansyah, Deputy Country Director, IRM,
    [Show full text]
  • Provider Indemnity Per 17 Januari 2020
    PROVIDERPROVIDER INDEMNITY INDEMNITY SWAKELOLA PER 17 JANUARI PER 17 JANUARI2020 2020 NO PROPINSI WILAYAH NAMA PROVIDER ALAMAT TELEPON COVERAGE TYPE PROVIDER JL. PROF A. MADJID IBRAHIM NO. 10, SIGLI, PIDIE, ACEH 24151 1 NANGGROE ACEH DARUSSALAM KAB. PIDIE KLINIK MUTIARA SIGLI 065321529 PHARMACY,RG,RJ Klinik RT:0 RW:0 Kec.: Dati2:KAB. PIDIE 2 NANGGROE ACEH DARUSSALAM KOTA LANGSA KLINIK & APOTEK KF 81 JL. TM.ZEIN NO.1E ,LANGSA RT:0 RW:0 Kec.: Dati2:KOTA LANGSA 064121020 PHARMACY,RJ Klinik JL. AHMAD YANI NO. 154-B LANGSA RT: RW: Kec.: Dati2:KOTA 3 NANGGROE ACEH DARUSSALAM KOTA LANGSA KLINIK DR. SYARBAINI, M.KES 08111753107 LAB,RG,RJ Klinik LANGSA JL. MERDEKA NO. 47 B -C LHOKSEUMAWE BANDA ACEH RT:0 4 NANGGROE ACEH DARUSSALAM KOTA LHOKSEUMAWE KLINIK & APOTEK KF 60 064541152 PHARMACY,RJ Klinik RW:0 Kec.: Dati2:KOTA LHOKSEUMAWE JL. ISKANDAR NO. 278 - 280, MEDAN RT:0 RW:0 Kec.: 5 SUMATRA UTARA KOTA MEDAN RUMAH SAKIT KHUSUSMATA SMEC 0614525058 PHARMACY,RI,RJ Klinik Dati2:KOTA MEDAN JL. SISINGAMANGARAJA NO.17 RT: RW: Kec.: Dati2:KOTA 6 SUMATRA UTARA KOTA MEDAN KLINIK SPESIALIS BUNDA 0617321666 GCU,PHARMACY,RG,RJ Klinik MEDAN 7 SUMATRA UTARA KOTA MEDAN KLINIK TELKOMEDIKA HEALTH CENTER MEDAN JL. TIMOR NO. 25 MEDAN RT:0 RW:0 Kec.: Dati2:KOTA MEDAN 0614101294 GCU,PHARMACY,LAB,RG,RJ Klinik Jl. International Bandara Kualanamu RT: RW: Kec.: Dati2:KOTA 8 SUMATRA UTARA KOTA MEDAN KLINIK KIMIA FARMA BANDARA KUALANAMU 0 RJ Klinik MEDAN Jl. Bakaran Batu No. 13/15 Kel. Lubuk Pakam, Medan, Sumatera 9 SUMATRA UTARA KOTA MEDAN KLINIK KIMIA FARMA LUBUK PAKAM 0 RJ Klinik Utara RT: RW: Kec.: Dati2:KOTA MEDAN Jl.
    [Show full text]
  • Towards Performance
    KOMUNIKATIF, TERBUKA, DAN BERSAHABAT EDISI 53 TAHUN 2019 TOWARDS EXCELLENTPERFORMANCE Pembentukan Kimia Farma Menjadi Pekan Olahraga dan Seni Semarak Health Risk Officer Kontributor dalam Acara Kimia Farma: Semua & Beauty Fest Kimia Farma Grup Internet of Things Indonesia Senang Semua Menang..!!! Di Yogyakarta GEMAKAEF 03 EDISI 53/2019 Salam PENASEHAT Direksi PT Kimia Farma (Persero) Tbk PENGARAH Direktur Utama PENANGGUNG JAWAB Salam Pemimpin Redaksi GM Sekretaris Perusahaan PEMIMPIN REDAKSI Halo Insan Kimia Farma di manapun Siti Anisa Husnu Anda berada. PENYUNTING/REDAKTUR Hilda Shinta Sinaga Kita kembali berjumpa setelah DOKUMENTASI melewati libur lebaran Idul Fitri dan Idul Nurhan Santoso Adha melalui majalah Gema Kaef edisi ADMINISTRASI DAN SIRKULASI 53 Tahun 2019. Salam sejahtera. Handoko Pada edisi kali ini, Gema Kaef kembali KOORDINATOR DAERAH menyajikan berita seputar perusahaan. M. Nuroni Muchtar (KFA Bandung) Tema kali ini adalah kinerja perusahaan Tommy Faisal (KFTD Jakarta) untuk mencapai operational excellent. Hendro Pramono (KFA Yogyakarta) Tema ini sangatlah penting, karena Choirul Anwar (Marketing Jakarta) sebagai perusahaan farmasi yang beragam kunjungan kerja. Pembaca yang Budiman, kita semua REPORTER DAERAH besar, Kimia Farma harus senantiasa Waskito Legowo (Jakarta) memiliki performa yang semakin baik, berharap ke depan perusahaan yang kita DG Kumarsana (KFA Mataram) baik dari segi proses, produk, maupun cintai bersama ini bisa semakin maju Muhammad Sjachrun (KFA Balikpapan) pelayanan. Oleh sebab itu, Kimia dan mampu berperan meningkatkan Agung Gustiman (R&D Bandung) Farma mengadakan kegiatan assesmen kesejahteraan masyarakat utamanya di Benedictus Agung Pramono (KFA Semarang) Muhar (KFA Jayapura) untuk mengukur kinerja perusahaan bidang kesehatan. Untuk mewujudkan Ramlan Lubis (KFA Bukittinggi) sesuai kaidah yang telah diatur oleh itu semua, kita perlu semangat yang kuat Sujiono Radi Saputro (KFA Surabaya) Kementrian BUMN.
    [Show full text]
  • Company Update Q2
    Company Update PT Kimia Farma Tbk Q2 – 2020 Healthy Growth Performance Speaker Mr. Pardiman . Finance Director PT Kimia Farma Tbk (KAEF) . Indonesian Citizen . Education & Training: . Master of Management from Diponegoro University . Bachelor of Economics Management from Diponegoro University . BUMN Executive Leadership Program . IFA Strategic Forum . Employment History: . Finance Director PT Bio Farma (Persero) (2018-2019) . Finance Director PT Perum Bulog (2017-2018) . Finance Director PT Petrokimia Gresik (2016-2017) . President Commisioner PT Kawasan Industri Gresik (2016-2017) . Director of Consumer, Micro and Funding PT Bank BRI Syariah (2015-2017) 2 Agenda 1 MARKET OVERVIEW 2 COMPANY OVERVIEW 3 FINANCIAL HIGHLIGHT 4 BUSINESS EXPANSION & INVESTMENT 5 OUR RETAIL BUSINESS-KIMIA FARMA APOTEK 1 MARKET OVERVIEW Indonesia Pharmaceutical Market (Q2/2020) Indonesia pharmaceutical market decrease at -1.0% in MAT Q2/2020 • Ethical Branded still growth 1.2% and 100,000 9 Free Sales growth 0.9% in MAT 90,000 8 8.0 MNC ETHICAL Q2/2020, but for the Unbranded 7 80,000 21,983 DOMESTIC BRANDED, Generic decrease -9.8%. 21,598 21,932 FREE SALES, 21.9% 70,000 6 19,668 25.5% 5 • Unbranded Generic decrease was due 60,000 MNC 4 FREE UNBRANDED to the fact that the budget from 50,000 2.8 40,782 SALES GENERIC, 0.1% Government for Unbranded Generic 41,041 41,972 3 30.7% 40,000 38,825 that should have been spent was 2 diverted to spending on Covid-19 30,000 MNC FREE ETHICAL 1 SALES, 5.2% 69.3% 4,481 related products, resulting in a fairly 20,00 3,836 4,005 4,196 high decline.
    [Show full text]
  • Garam Farmasi Raih Sertifikat Halal Dari MUI Kimia Farma Bukukan Laba Bersih Rp271,5 M “Indonesia Corsec & Corp. Comm Awar
    EDISI 45 TAHUN 2017 KOMUNIKATIF, TERBUKA, DAN BERSAHABAT KOMANDAN BARU KIMIA FARMA Peluncuran “Indonesia Corsec & Corp. Kimia Farma Garam Farmasi Kimia Farma Sabet Kartu BUMN Comm Award 2017” untuk Bukukan Laba Bersih Raih Sertifikat Halal Digital Popular Brand Kimia Farma Rp271,5 M dari MUI Award 2017 SALAM Butuh Dukungan Kita Semua Ditetapkannya Dewan Direksi Kimia Farma yang baru dalam RUPS PT Kimia Farma (Persero) Tbk, belum lama ini, membawa secercah harapan baru bagi kemajuan dan pengembangan perusahaan ke depan. Karena itulah, kita sebagai SDM di perusahaan ini mari secara bahu membahu mendukung dan menyukseskan program kerja dan Eddy Murianto strategi usaha manajemen. Pemimpin Redaksi ada Kamis, 20 April 2017 yang (Direktur Utama); I.G.N. Suharta Pasalnya, sebagus apapun program lalu, PT Kimia Farma (Persero) Wijaya (Direktur Keuangan); Pujianto kerja maupun strategi usaha yang P Tbk telah menyelenggarakan (Direktur Pengembangan Bisnis); dirancang direksi bila segenap SDM Rapat Umum Pemegang Saham Verdi Budidarmo (Direktur Produksi & yang ada di perusahaan yang kita (RUSP) tahunan untuk Tahun Buku Supply Chain); serta Arief Pramuhanto cintai ini, tidak mendukungnya secara 2016. Dalam RUPS tersebut, (Direktur Umum & Human Capital). penuh maka target kinerja yang telah Kementerian BUMN selaku pemegang ditetapkan manajemen pun, agaknya saham mayoritas PT Kimia Farma Pergantian Direksi Kimia Farma bakal sulit bisa tercapai secara optimal. (Persero) Tbk memutuskan untuk tersebut, tentu mendatangkan merombak susunan Dewan Direksi secercah harapan baru bagi kemajuan Untuk itu, memacu semangat bekerja di Kimia Farma. Dari 5 anggota direksi dan pengembangan perusahaan unit kerja kita masing-masing di Kimia Kimia Farma, hanya satu yang tetap ke depan. Apalagi, mereka yang Farma ini memang harus senantiasa dipertahankan, sedangkan selebihnya duduk dalam keanggotaan direksi kita gelorakan bersama-sama.
    [Show full text]
  • JAWA BARAT May 2020.Pdf
    NO STATE CITY PROVIDER_NAME ADDRESS TEL_NO 1 JAWA BARAT BANDUNG RSUD. AL IHSAN Jl. Ki Astramangala. Baleendah '022-5940872/5941719/5941729/5940770/87799431 2 JAWA BARAT BANDUNG KLINIK CIBOLERANG SEHAT Jl. Cibolerang No.90 Rt.01/Rw.06. Margahayu Utara. Babakan Ciparay '022-5408979 3 JAWA BARAT BANDUNG KF 0495 BUAH BATU Jl.Terusan Buah Batu No. 265. Kujangsari. Bandung Kidul. Kota Bandung '022-87770227/08112157658 4 JAWA BARAT BANDUNG RS. CAHYA KAWALUYAN Jl. Parahyangan Km.3 Kav.Hos Padalarang '022-6803700 5 JAWA BARAT BANDUNG LAB. PRODIA MTC Metro Indah Mall Blok B No.5. Jl. Soekarno Hatta. Bandung '022-7536256 6 JAWA BARAT BANDUNG OPTIK SEIS PARIS VAN JAVA Ground Floor Unit G-B-52 Jl. Sukajadi No. 137 - 139 Bandung '(022) 82063571 7 JAWA BARAT BANDUNG RUMAH VAKSINASI SARIWANGI Jl. Sariwangi No 4. Desa Cihanjuang. Kec. Parongpong. Kab. Bandung Barat '082116953993 8 JAWA BARAT BANDUNG KF CIPACING Jl. Raya Rancaekek Rt 01 Rw 08 Dusun Munggang Desa Mekargalih Sumedang Cipacing. Jatinangor. Kota Bandung '022-7790626/08112157662 9 JAWA BARAT BANDUNG FDC DENTAL CLINIC (BANDUNG) Jl. Kebon Kawung No.2. Pasir Kaliki. Kec. Cicendo '022-20526914 10 JAWA BARAT BANDUNG OPTIK MELAWAI PARIS VAN JAVA II Paris Van Java Ii Glamour Floor Unit Gl-C-01 '(022-82063733) 11 JAWA BARAT BANDUNG KLINIK UTAMA ELIM Jl. Jenderal Sudirman No. 190. Rt.05 Rw.07. Kebon Jeruk. Andir '022 - 6029696 / 6029797 12 JAWA BARAT BANDUNG KIMIA FARMA GEGERKALONG Jl. Gegerkalong Hilir No. 33. Kec. Sukasari '022 - 82004505 13 JAWA BARAT BANDUNG KF KOPOSARI Jl. Kopo Cirangrang No. 523. Kopo.
    [Show full text]
  • Tingkat Kepuasan Konsumen Terhadap Pelayanan Resep Di Apotek Kimia Farma 286 Padang Asri
    I NYOMAN GEDE TRI SUTRISNA. Jurnal Ilmiah Medicamento 2(2) 2016; 34-38 TINGKAT KEPUASAN KONSUMEN TERHADAP PELAYANAN RESEP DI APOTEK KIMIA FARMA 286 PADANG ASRI (CUSTOMER SATISFACTION LEVEL OF PRESCRIPTION SERVICE IN KIMIA FARMA PHARMACY 286 PADANG ASRI) I N. G. TRI SUTRISNA1•, PUTU AYU WIDYA GALIH MEGA PUTRI2, KADEK DUWI CAHYADI1 1Akademi Farmasi Saraswati Denpasar, Bali, 2Apotek Kimia Farma 286 Padang Asri, Bali Abstrak: Pelayanan kesehatan yang baik dapat meningkatkan kualitas kesehatan individu. Kesehatan merupakan bagian yang penting guna meningkatkan kualitas hidup dari masing-masing individu. Pelayanan kefarmasian merupakan salah satu bagian dari pelayanan kesehatan. Apotek merupakan salah satu sarana atau tempat pelayanan kefarmasian khususnya pelayanan resep. Apotek Kimia Farma sendiri merupakan apotek yang sudah dikenal oleh masyarakat luas khususnya di Bali dengan pelayanan yang ramah, sikap yang baik, kejelasan, dan ketepatan pemberian informasi yang lengkap, kecepatan dan ketelitian dalam pelayanan. Penelitian tentang tingkat kepuasan pasien terhadap pelayanan resep di Apotek kimia Farma 286 Padang Asri merupakan penelitian deskriptif menggunakan kuisioner yang disebarkan kepada 50 responden yang melakukan pengambilan obat dengan resep di apotek tersebut. Penilaian didasarkan pada 5 (lima) dimensi yaitu dimensi responsiveness (ketanggapan pelayanan), dimensi reliability (keandalan pelayanan), dimensi assurance (keyakinan/jaminan), dimensi empathy (perhatian untuk memahami kebutuhan pelanggan) dan dimensi tangible (sarana fisik, perlengkapan dan pegawai). Dari hasil perhitungan dan analisa data yang diperoleh skor rata-rata pada setiap indikator sebagai berikut indikator responsiveness dengan skor rata-rata 3,14 dengan klasifikasi puas, indikator reliability dengan skor rata-rata 3,13 dengan klasifikasi puas, indikator assurance dengan skor rata-rata 3,28 dengan klasifkasi sangat puas, indikator empathy dengan skor rata-rata 3,17 dengan klasifikasi puas, indikator tangible dengan skor rata-rata 3,19 dengan klasifikasi puas.
    [Show full text]